NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
146 trialsNCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01972919 2025-10-27
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04068103 2025-05-07
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NRG Oncology
Phase 2/3 Active not recruiting
NCT02734290 2025-03-10
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT00881621 2025-03-03
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT03916510 2025-02-06
CEDAR
University of Oxford
Phase 1 Completed
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT02861300 2024-12-19
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03487666 2024-12-03
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Georgetown University
Phase 2 Completed
NCT03872388 2024-10-02
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT03641547 2024-07-18
CHARIOT
University of Oxford
Phase 1 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT01387295 2023-12-11
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Herlev Hospital
Phase 2 Completed
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00093379 2023-04-18
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT00130533 2023-03-31
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00291486 2022-10-10
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01498458 2022-06-10
PazoX
GBG Forschungs GmbH
Phase 1 Completed
NCT01226732 2022-03-08
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01360593 2022-03-08
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
University of Pittsburgh
Phase 2 Completed
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT00193128 2021-11-24
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT03093870 2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3 Completed
NCT02393755 2021-07-08
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01459614 2021-05-19
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT02550743 2021-03-12
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
Brown University
Phase 1 Terminated
NCT01781403 2021-02-04
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Asan Medical Center
Phase 1 Completed
NCT02010567 2020-11-03
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03515941 2020-10-12
GABLE
Baylor College of Medicine
Phase EARLY_PHASE1 Terminated
NCT00266279 2020-09-03
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
University of Louisville
Phase 2 Completed
NCT01208103 2020-09-03
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
M.D. Anderson Cancer Center
Phase 2 Completed